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Purpose: The purpose of this study was to compare once-daily tacrolimus with 
twice-daily tacrolimus in terms of safety, efficacy, and patient satisfaction. Materi-
als and Methods: This prospective, randomized, open-label, multicenter study 
was conducted at three institutes. Patients in the investigational group were con-
verted from tacrolimus twice daily to the same dose of extended-release tacrolim-
us once daily at 1 month post-transplantation, while patients in the control group 
were maintained on tacrolimus twice daily. The efficacies, safeties, and patient sat-
isfaction for the two drugs at 6 months post-transplantation were compared. Re-
sults: Sixty patients were enrolled and randomized to the investigational group (28 
of 29 patients completed the study) or the control group (26 of 31 patients com-
pleted the study). At 6 months post-transplantation, composite efficacy failure 
rates including the incidences of biopsy-confirmed acute rejection in the investiga-
tional and control groups were 0% and 10.7%, respectively; patient survival was 
100% in each group. No difference in estimated glomerular filtration rate values 
were observed at 6 months post-transplantation (p=0.97). The safety and satisfac-
tion profile (immunosuppressant therapy barrier scale) of once-daily tacrolimus 
was comparable with that of twice-daily tacrolimus (p=0.35). Conclusion: Con-
version from twice-daily tacrolimus to once-daily tacrolimus one month after 
transplantation is safe and effective.
Key Words:   Acute rejection, efficacy, extended-release tacrolimus, kidney trans-
plantation, safety
INTRODUCTION
Once-daily tacrolimus is an extended-release formulation of tacrolimus that can be 
administered once daily in the morning. Previous studies have demonstrated the 
non-inferiority of once-daily tacrolimus (Advagraf®, Astellas Pharma Inc., Tokyo, 
Japan) to twice-daily tacrolimus (Prograf®, Astellas Pharma Inc., Tokyo, Japan) in 
terms of its efficacy and safety for de novo renal transplant recipients. Studies have 
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with the following doses: 500 mg on the day of operation 
and 250 mg on the day after, and corticosteroids were ta-
pered to a maintenance dose of more than 5 mg a day (pred-
nisolone or equivalent) orally twice or once a day. Target 
dose of mycophenolate mofetil was 1000--2000 mg/day, 
orally twice a day, for both groups throughout the study pe-
riod. Tacrolimus (Prograf ®) was initiated at 0.05--0.1 mg/kg, 
starting on the day before transplantation. Within a month 
after transplantation, dosages were individually adjusted to 
achieve a trough blood level between 5 and 15 ng/mL. Pa-
tients in the investigational group were converted to the 
same milligram-for-milligram daily dose of once-daily ta-
crolimus (Advagraf ®, Astellas Pharma Inc., Tokyo, Japan) 
on the 28th day post-transplantation and were then main-
tained at tacrolimus trough levels of 3 to 12 ng/mL through-
out the study. The patients in the control group continued to 
take twice-daily tacrolimus (Prograf ®) at targeted blood 
trough levels of 3 to 12 ng/mL from 1 month post-trans-
plantation. 
Efficacy and safety 
Efficacy and safety analyses were performed using a modi-
fied intent-to-treat population composed of all randomized 
patients that received at least one dose of study drug. A 
composite primary efficacy endpoint was assessed: that is, 
efficacy failure rate at 6 months post-transplantation, in-
cluding any mortality, graft failure (return to dialysis for 
>30 days or re-transplant), treatment for biopsy-confirmed 
acute rejection (BCAR), or loss to follow-up. The latter was 
defined as a lack of follow-up information for at least 3 
months (90 days). Secondary endpoints incuded patient and 
graft survival rates at 6 months, incidences of BCAR at 1 
and 6 months, estimated glomerular filtration rate (eGFR) 
as determined using the Nankivell method at 6 months,10 
the amount of proteinuria in 24-hour urine at 6 months, cre-
atinine clearance in 24-hour urine at 6 months, and the im-
munosuppressant therapy barrier scale (ITBS). Adverse 
events (AE) were recorded and coded during the study pe-
riod. An adverse event was defined as any untoward medi-
cal occurrence, including an exacerbation of a per-existing 
condition, in a patient in a clinical investigation who re-
ceived a pharmaceutical product. The event did not neces-
sarily have a causal relationship with this treatment. The se-
verity grade of AE was defined as: 1) mild, usually transient 
in nature and generally not interfering with normal activi-
ties; 2) moderate, sufficiently discomforting to interfere 
with normal activities; and 3) severe, prevents normal ac-
even demonstrated that kidney transplant recipients con-
verted to once-daily tacrolimus could be safely maintained 
using the same therapeutic monitoring and patient care 
techniques used for twice-daily tacrolimus.1-5 
Once-daily tacrolimus may improve adherence, resulting 
in better post-transplant outcomes. Successful outcomes af-
ter renal transplantation depend on patient adherence with 
immunosuppressive medications, because the effectiveness 
of medications in terms of preventing acute rejection after 
transplantation depend not only on the right choice of drugs, 
but also on active patient cooperation.6-9
However, prospective clinical trials have yet to assess con-
version of twice-daily tacrolimus to once-daily tacrolimus 
for the specific same period.
The primary endpoint of this study was to determine the 
safety and efficacy of once-daily tacrolimus in kidney trans-
plant recipients converted from twice-daily tacrolimus one 
month after transplantation. The secondary endpoint was to 
compare patient satisfaction between once-daily and twice-
daily tacrolimus using the immunosuppressant therapy bar-
rier scale (ITBS). 
MATERIALS AND METHODS
Study design
This open-label, randomized (1:1), double arm, multicenter, 
non-inferiority, conversion study was conducted at three 
transplant centers in Korea from April 2010 to June 2012. 
The study protocol was approved by the Institutional Re-
view Board at all participating centers to ensure that study 
procedures were in accord with the Helsinki Declaration. 
Eligibility criteria
The study inclusion criteria were an age between 20 and 65 
years and recipient of a primary kidney transplant from a de-
ceased or living donor between 15 and 65 years of age. The 
study exclusion criteria were receipt or scheduled receipt of 
an organ transplant other than a kidney or scheduled receipt 
of a kidney from a non-heart beating or ABO blood group 
incompatible or lymphocyte cross match positive donor. 
Immunosuppression
All recipients were administered twice-daily tacrolimus 
(Prograf ®, Astellas Pharma Inc.,Tokyo, Japan) with prednis-
olone and mycophenolate mofetil until 1 month post-trans-
plantation. Methyl-prednisolone was injected intravenously 
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calculated to have 80% power, 25% non-inferiority margin, 
and a 10% drop out rate. To allow for discontinuations, 60 
patients (n=30 per group) were initially randomly assigned.
RESULTS
 
Study population
In total, 60 patients were enrolled in this study and random-
ized to either the investigational group (n=29) or the control 
group (n=31). Fifty-four (90.0%) patients remained on study 
medication at 6 months post-transplantation. One patient 
(3.4%) in the investigational group and 5 patients (16.1%) in 
the control group prematurely discontinued medication dur-
ing follow-up. The reasons for premature discontinuations 
were adverse events (n=1), withdrawal of consent (n=3), 
graft loss (n=1), and protocol deviation (n=1). Donor and 
recipient characteristics were comparable in the two study 
groups (Table 1).
Primary composite endpoint 
Composite efficacy failure rates including the incidence of 
biopsy-confirmed acute rejection until 6 months post-trans-
plantation were 0% in the investigational group and 10.7% 
in the control group, and the investigational group was sta-
tistically non-inferior to the control group. One graft loss in 
the control group and no patient death in either group were 
recorded. No statistical differences were observed between 
the groups in terms of Kaplan-Meier estimates of patient 
proportions free of composite efficacy failure at 6 months 
post-transplantation (100% in the investigational group and 
89.3% in the control group; p=0.236). 
Incidence of biopsy-confirmed acute rejection
The incidences of treated BCAR within 6 months of trans-
plantation were not significantly different between the two 
groups: 0% in the investigational group and 10.7% in the 
control group (p=0.075), which was statistically non-inferi-
or to the investigational group.
Graft renal function
Mean eGFRs (by the Nankivell method) in the investiga-
tional group were 40.2±6.9 mL/min/1.73 m2 at 1 month, 
41.7±6.3 mL/min/1.73 m2 at 2 months, 41.2±6.0 mL/
min/1.73 m2 at 4 months, and 41.8±6.1 mL/min/1.73 m2 at 
6 months post-transplantation, and in the control group 
were 41.0±5.2  mL/min/1.73 m2 at 1 month, 41.6±5.3 mL/
tivities. Serious adverse events (SAEs) were defined as any 
AE undesirable signs, symptoms, or medical conditions 
that met any one of the following criteria: 1) was fatal or 
life-threatening, 2) resulted in persistent or significant dis-
ability/incapacity, 3) required hospitalization or prolonga-
tion of existing hospitalization, 4) was a congenital anoma-
ly/birth defect, or 5) was an important medical event that 
might jeopardize the patient and might require medical or 
surgical intervention to prevent one of the outcomes listed 
above. Differences between adverse event incidences and 
the incidences of predefined potentially clinically signifi-
cant laboratory values in the two study groups were as-
sessed and analyzed.
Patient satisfaction using ITBS
ITBS is a 13-item scale that measures barriers to immuno-
suppressant adherence in transplant patients. ITBS was mea-
sured at 6 months post-transplantation. Each item was mea-
sured on a 5-point scale (1=strongly disagree, to 5=strongly 
agree) assessing respondent agreement with each statement. 
Items consisted of questions about how often: 1) they for-
got to take their immunosuppressants, 2) were careless 
about taking their immunosuppressants, 3) stopped taking 
their immunosuppressants because they felt worse, and 4) 
missed taking their immunosuppressants for any reason.11
Evaluation schedule
Study visits took place prior to transplantation (baseline) and 
at 1, 2, 4, and 6 months post-transplantation. At each visit, a 
complete physical examination was performed and laborato-
ry values concerning kidney, liver, hematology, proteinuria, 
and tacrolimus in blood were measured. Blood pressure, 
weight, and any problems between visits were documented. 
All adverse and severe adverse events were documented.
Statistical analyses
All assessments of non-inferiority were made using a pre-
specified margin of 25% with a 0.05 level of significance. 
Frequency distributions were plotted for categorical vari-
ables. The χ² test or Fisher’s exact test were used to compare 
the two treatment groups. Descriptive statistics were ana-
lyzed as continuous variables using Student’s t-test. Continu-
ous variables were expressed as means±standard deviations. 
Based on reference to a previous study, the efficacy fail-
ure rates at post-transplant 6 months for the control and in-
vestigational groups were 14.0% and 15.1%, respectively.12 
A sample size of 25 patients per each treatment group was 
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plantation were comparable between the two groups (71.4% 
of patients in the investigational group and 75.0% in the 
control group; p=0.763), and incidences of SAEs were also 
comparable (14.7% in the investigational group and 15.5% 
in the control group; p=0.415). The incidences of adverse 
events by system organ class were generally similar be-
tween the groups, and most were mild-to-moderate in se-
verity (Table 3).
Immunosuppressant therapy barrier scale (ITBS) 
The summed score of the 13 items of the ITBS (highest val-
ue possible 65 and lowest 13) of the investigational group at 
6 months post-transplantation was 17.5±3.1, which was 
comparable to that of the control group (18.4±4.0; p=0.345).
DISCUSSION
As far as we know, there has not been a prospective trial 
designed to assess conversion from twice-daily tacrolimus 
to once-daily tacrolimus at the same point in time, one 
min/1.73 m2 at 2 months, 42.5±5.9 mL/min/1.73 m2 at 4 
months, and 41.9±5.8 mL/min/1.73 m2 at 6 months post-
transplantation. Group renal functions were not statistically 
different at any time (p>0.05). 
Measured creatinine clearance by 24-hour urine collec-
tion at 6 months post-transplantation were similar between 
the two groups (64.1±21.5 mL/min/1.73 m2 in the investi-
gational group and 63.64±21.3 mL/min/1.73 m2 in the con-
trol group; p=0.933). 
Excreted protein amounts at 6 months post-transplanta-
tion were similar at 104.3±84.4 and 91.4±83.4 mg per day 
in the investigational and control groups (p=0.589).
Doses, blood trough levels, and tacrolimus dose 
adjustments
At follow-up visits, most subjects did not require dose ad-
justment. The mean daily doses and whole blood concen-
trations of tacrolimus are summarized in Table 2.  
Adverse events
Overall incidences of adverse events at 1 month post-trans-
Table 1. Baseline Demographics and Clinical Characteristics of the Study Population (ITT Population)
Investigational group (n=29) Control group (n=31) p value
Recipient characteristics
    Age, yrs±SD   44.5±10.5   46.9±10.5 0.363
    Male, n (%) 17 (58.6) 16 (57.1) 0.785
    BMI, m2/kg±SD 22.3±2.9 24.0±3.8 0.070
    Primary disease, n (%) 0.961
        Hypertension/nephrosclerosis   8 (27.6)   7 (22.6)
        Glomerulonephritis/glomerular disease   5 (17.2)   4 (12.9)
        Diabetes mellitus   6 (20.7)   5 (16.1)
        Polycystic disease 1 (3.4) 0 (0.0)
        Unknown/others   9 (31.1) 15 (48.4)
    Current dialysis, n (%) 0.823
        HD 24 (82.8) 24 (77.4)
        CAPD   3 (10.3)   5 (16.1)
        None 2 (6.9) 2 (6.5)
    Number of HLA mismatches, n (%) 0.773
        0--2   6 (20.7)   6 (19.4)
        3--4 13 (44.8) 16 (51.6)
        5--6 10 (34.5)   9 (29.0)
Donor characteristics
    Age, yrs±SD   42.5±12.6 42.0±9.9 0.842
    Male, n (%)   13 (44.8) 15 (48.4) 0.587
    Types, n (%) 0.364
        Living 17 (58.6) 16 (51.6)
        Deceased 12 (41.4) 15 (48.4)
ITT, intention-to-treat; BMI, body mass index; HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; HLA, human leukocyte antigen.
Continuous variables are expressed as the mean±standard deviation (SD) and their p-values were calculated with t-test. Categorical variables are ex-
pressed as number (%) and their p-values were calculated with Fisher’s exact test.
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blood trough levels of once-daily tacrolimus were lower 
than those of twice-daily tacrolimus, especially at post-trans-
plant 4 and 6 months. The rate of increasing tacrolimus 
dose was higher in the once-daily tacrolimus group than 
twice-daily tacrolimus group. Therefore, in order to prevent 
development of acute rejection, especially during the early 
post-transplant period, blood trough levels should be cau-
tiously monitored when twice-daily tacrolimus is converted 
to once-daily. A recent report revealed another pharmacoki-
netic difference between once-daily and twice-daily tacroli-
mus regarding the intravariability of blood trough concen-
tration (C0), which was significantly lower for once-daily 
tacrolimus.18
Although the present study was not powered to test for 
superiority, the BCAR rate at 6 months was lower for once-
daily tacrolimus. This finding suggests that the efficacy of 
once-daily tacrolimus is at least equivalent to that of twice-
daily tacrolimus. Only when the blood trough levels are ap-
propriately maintained, tacrolimus-based immunosuppres-
sion should be enough to suppress acute rejection regardless 
of its frequency of dosing (once-daily or twice-daily). Pre-
vious studies have failed to demonstrate the equivalence of 
month after transplantation, which is the main reason why 
we conducted this trial. Because many transplant doctors 
are accustomed to using twice-daily tacrolimus and main-
taining a dose of tacrolimus that is usually determined at 
one month post-transplantation, we considered one month 
after transplantation as an optimal timing for conversion of 
twice-daily tacrolimus to once-daily tacrolimus. The results 
of the present clinical trial show that the once-daily tacroli-
mus is effective with good tolerability and safety when ad-
ministered from 1 month after transplantation. In the pres-
ent study, during the 6-month post-transplantation period, 
no graft was lost and no patient death occurred in the inves-
tigational group. Furthermore, no episode of biopsy-proven 
acute rejection was encountered in the investigational group.
Despite the finding that once-daily tacrolimus provided 
more stable drug blood concentrations than twice-daily ta-
crolimus,13 it was found to be necessary to use higher doses 
of once-daily tacrolimus to reach targeted trough levels af-
ter conversion from twice-daily tacrolimus, which concurs 
with previous reports.14-17 As shown in the results, adminis-
tered doses of once-daily tacrolimus were higher than those 
of twice-daily tacrolimus after conversion, and the mean 
Table 2. Tacrolimus Doses, Blood Levels, and Dose Adjustment Over the Time (PP Population)
Investigational group (n=28) Control group (n=26) p value
Dose (mg/day)
    Month 1 6.1±3.4 6.2±3.6 0.899
    Month 2 6.2±3.2 5.5±2.9 0.380
    Month 4 6.1±3.2 5.3±2.8 0.308
    Month 6 6.7±3.1 5.0±2.7 0.161
Blood trough level (ng/mL)
    Month 1 7.9±3.7 7.6±3.9 0.760
    Month 2 5.4±1.9 6.7±2.8 0.052
    Month 4 6.0±2.1 7.8±2.9 0.011
    Month 6 5.6±2.1 7.5±3.2 0.016
PP, per-protocol.
Continuous variables are expressed as the mean±standard deviation and their p-values were calculated with t-test. 
Table 3. Adverse Events after 1 Month Post-Transplantation (ITT Population)
Investigational group (n=29) Control group (n=31) p value
Any AE 20 (70.0) 21 (67.7) 0.782
SAEs 10 (34.5) 13 (41.9) 0.513
Severe AEs 0 (0.0) 1 (3.2)
AEs leading to study drug discontinuation 0 (0.0) 0 (0.0)
Most frequently reported AEs (≥20% of patients in any treatment group)
    Gastro-intestinal system disorders   8 (27.6)   7 (22.6)
    Metabolic and nutritional disorders   6 (20.7)   6 (19.4)
    Respiratory system disorders   6 (20.7)   7 (22.6)
    Urinary system disorders   4 (13.8)   6 (19.4)
ITT, intention-to-treat; AE, adverse event; SAE, serious adverse event.
Categorical variables are expressed as number (%) and their p-values were calculated with Fisher’s exact test.
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608. 
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transplant recipients. Am J Transplant 2011;11:1965-71. 
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quency and impact of nonadherence to immunosuppressants after 
renal transplantation: a systematic review. Transplantation 2004; 
77:769-76.
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tion. J Am Soc Nephrol 2005;16:1839-48.
8. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei 
Med J 2004;45:1127-31.
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suppression. Transplant Proc 2005;37:2675-8.
10. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predict-
ing glomerular filtration rate after kidney transplantation. Trans-
plantation 1995;59:1683-9.
11. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Develop-
ment and validation of an immunosuppressant therapy adherence 
barrier instrument. Nephrol Dial Transplant 2005;20:181-8.
12. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the 
prophylaxis of transplant rejection in renal or liver allograft recipi-
ents. Drugs 2007;67:1931-43.
13. Kurnatowska I, Krawczyk J, Oleksik T, Nowicki M. Tacrolimus 
dose and blood concentration variability in kidney transplant re-
cipients undergoing conversion from twice daily to once daily 
modified release tacrolimus. Transplant Proc 2011;43:2954-6. 
14. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced 
C0 concentrations and increased dose requirements in renal al-
lograft recipients converted to the novel once-daily tacrolimus for-
mulation. Transplantation 2010;90:523-9. 
15. Jelassi ML, Lefeuvre S, Karras A, Moulonguet L, Billaud EM. 
Therapeutic drug monitoring in de novo kidney transplant receiv-
ing the modified-release once-daily tacrolimus. Transplant Proc 
2011;43:491-4.
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Proc 2009;41:2115-7. 
17. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le 
the efficacy of once-daily versus twice-daily tacrolimus in 
de novo kidney transplant patients.3,4 In the present study, 
we initiated immunosuppression with twice-daily tacrolimus 
during this critical period, and then converted to once-daily 
tacrolimus. This conversion at 1 month post-transplantation 
may have avoided the risk of acute rejection immediately 
after transplantation, because this period is vulnerable to 
development of acute rejection. In addition, it is easier to 
adjust optimal blood trough levels using twice-daily tacroli-
mus than once-daily tacrolimus.
Generally, adherence has been reported to increase from 
59% for 3 times daily dosing regimens to 83% for once 
daily regimens,19 which leads to the conclusion that reduc-
ing the dosage frequency is one of the most important means 
of improving adherence. However, all kidney transplant pa-
tients enrolled in this study were taking adjunctive immu-
nosuppressants, such as glucocorticoid and mycophenolate 
mofetil, which required twice-daily dosing. We believe that 
this explains why ITBS scores were not found to differ sig-
nificantly in our two groups (p=0.345). The limitations of 
this study include that it could not provide evidence of drug 
adherence associated with the dosage frequency and that it 
failed to demonstrate only once-daily drug as statistically 
superior for this study population who were taking con-
comitant medications twice a day.
In conclusion, conversion to once-daily tacrolimus at 1 
month after kidney transplantation was found to be non-infe-
rior in terms of efficacy and safety to twice-daily tacrolimus. 
In terms of patient satisfaction, despite once-daily tacrolimus 
would be partly useful to reducing the frequency of dosing, it 
failed to be statistically superior for this study population 
who were taking concomitant medications twice a day.
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